David J. Blanchard

Array ( [id] => 6664088 [patent_doc_number] => 20030203414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-10-30 [patent_title] => 'COMPOUNDS THAT INHIBIT THE INTERACTION BETWEEN SIGNAL-TRANSDUCING PROTEINS AND THE GLGF (PDZ/DHR) DOMAIN AND USES THEREOF' [patent_app_type] => new [patent_app_number] => 09/230111 [patent_app_country] => US [patent_app_date] => 1999-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 8915 [patent_no_of_claims] => 120 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0203/20030203414.pdf [firstpage_image] =>[orig_patent_app_number] => 09230111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 680581 [patent_doc_number] => 07084239 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-08-01 [patent_title] => 'Cancer peptides of NY-ESO-1/CAG-3' [patent_app_type] => utility [patent_app_number] => 09/529206 [patent_app_country] => US [patent_app_date] => 1998-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 22 [patent_no_of_words] => 18452 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/084/07084239.pdf [firstpage_image] =>[orig_patent_app_number] => 09529206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5908048 [patent_doc_number] => 20020142974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-03 [patent_title] => 'IMMUNE ACTIVATION BY DOUBLE-STRANDED POLYNUCLEOTIDES' [patent_app_type] => new [patent_app_number] => 09/151612 [patent_app_country] => US [patent_app_date] => 1998-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 42613 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20020142974.pdf [firstpage_image] =>[orig_patent_app_number] => 09151612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 475735 [patent_doc_number] => 07227002 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2007-06-05 [patent_title] => 'Human antibodies that bind human 17-A1/EpCAM tumor antigen' [patent_app_type] => utility [patent_app_number] => 09/403107 [patent_app_country] => US [patent_app_date] => 1998-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 27 [patent_no_of_words] => 14203 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/227/07227002.pdf [firstpage_image] =>[orig_patent_app_number] => 09403107 [rel_patent_id] =>[rel_patent_doc_number] =>)